У нас вы можете посмотреть бесплатно IPO interview with Rubicon Research CEO Mr. Parag Sancheti and CFO Mr. Nitin Jajodia или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
🌞In this exclusive video conference interview, we sit down with Mr. Parag Sancheti, CEO of Rubicon Research, to discuss the company's insights and the company’s IPO (Initial Public Offering) in October 2025. 🚀 About Rubicon Research IPO (2025): Established in 1999, Rubicon Research is a specialty pharmaceutical formulations company with a complete focus on regulated markets. The company focuses on the development of pharmaceutical formulations across various dosage forms, including oral solids, liquids, nasal, ophthalmic, topical, injectable, fixed-dose combinations, and drug-device combinations. Rubicon and its subsidiaries had 72 active ANDAs, nine NDAs, and one OTC monograph approved, with 17 new products under review. IPO Dates: 9 – 13 Oct 2025 Price Band: 461 – 485 per share IPO Size: INR 1,377.5 crore Listing: NSE & BSE ✨ In this Interview, you’ll discover: ✅The vision and mission shaping the company’s future ✅Key financial strategies and market insights ✅ Leadership lessons from top executives ✅Key insights into the Rubicon Research IPO 2025 and its potential 👉 If you’re interested in company insights or IPO investments, this conversation with CEO Parag Sancheti and CFO Nitin Jajodia will give you valuable perspectives. #CEOInterview #CFOInsights #Leadership #ExclusiveInterview #CompanyGrowth #FinanceTalks #ipoinvestment #ipo #RubiconResearchIPO #CEOInterview #CFOInsights #PharmaIPO #InvestmentOpportunities #StockMarket2025 #BusinessStrategy #PharmaceuticalIndustry #IPOInsights #GreyMarketPremium